Left Ventricular Dysfunction - Pipeline Review, H1 2012

Global Markets Direct, June 2012, Pages: 48

Left Ventricular Dysfunction – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Left Ventricular Dysfunction - Pipeline Review, H1 2012', provides an overview of the Left Ventricular Dysfunction therapeutic pipeline. This report provides information on the therapeutic development for Left Ventricular Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Left Ventricular Dysfunction. 'Left Ventricular Dysfunction - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Left Ventricular Dysfunction.
- A review of the Left Ventricular Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Left Ventricular Dysfunction pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Left Ventricular Dysfunction.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Left Ventricular Dysfunction pipeline depth and focus of Left Ventricular Dysfunction therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Left Ventricular Dysfunction Therapeutic Products under Development, Key Players in Left Ventricular Dysfunction Therapeutics, Left Ventricular Dysfunction Pipeline Overview, Left Ventricular Dysfunction Pipeline, Left Ventricular Dysfunction Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Left Ventricular Dysfunction Overview
Therapeutics Development
An Overview of Pipeline Products for Left Ventricular Dysfunction
Left Ventricular Dysfunction Therapeutics under Development by Companies
Left Ventricular Dysfunction Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Left Ventricular Dysfunction Therapeutics – Products under Development by Companies
Left Ventricular Dysfunction Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Left Ventricular Dysfunction Therapeutics Development
Acorda Therapeutics, Inc.
Sigma-Tau S.p.A.
Capricor Inc.
Left Ventricular Dysfunction – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Istaroxime - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GGF2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RHB-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Natrecor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Human Mesenchymal Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Human Bone Marrow Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CPI-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enalapril + Carvedilol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Human Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Bone Marrow Mononuclear Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bromocriptine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-3 Polyunsaturated Fatty Acids - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Heparin + Intralipid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bone Marrow Derived Mononuclear Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Left Ventricular Dysfunction Therapeutics – Drug Profile Updates
Left Ventricular Dysfunction Therapeutics – Discontinued Products
Left Ventricular Dysfunction Therapeutics - Dormant Products
Left Ventricular Dysfunction – Product Development Milestones
Featured News & Press Releases
Sep 06, 2007: Teva Announces Approval And Shipment Of Generic Coreg Tablets
Jun 09, 2004: Teva Announces Tentative Approval Of Carvedilol Tablets
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Left Ventricular Dysfunction, H1 2012
Products under Development for Left Ventricular Dysfunction – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Acorda Therapeutics, Inc., H1 2012
Sigma-Tau S.p.A., H1 2012
Capricor Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Left Ventricular Dysfunction Therapeutics – Drug Profile Updates
Left Ventricular Dysfunction Therapeutics – Discontinued Products
Left Ventricular Dysfunction Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Left Ventricular Dysfunction, H1 2012
Products under Development for Left Ventricular Dysfunction – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Male Sexual Dysfunction - Pipeline Review, H1 2013
• Male Sexual Dysfunction - Pipeline Review, H1 2012
• Erectile Dysfunction – Pipeline Review, H1 2013
• Dysautonomia (Autonomic Dysfunction) - Pipeline Review, H2 2012
• Erectile Dysfunction - Pipeline Review, H2 2012
• Erectile Dysfunction - Pipeline Review, H1 2012
• Premature Ejaculation – Pipeline Review, H1 2013
• Male Sexual Dysfunction - Pipeline Review, H2 2012
• Burns - Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013